Bispecific Antibody Phase 3 Licensing Benchmarks
Deal economics across 6 transactions with 5 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$1.3B
5 deals with terms
Median Total Value
$5.2B
Upfront + milestones
Royalty Range
10.7%--19.7%
Average low--high
Deal Count
6
2020--2025
The median upfront payment for phase 3 bispecific antibody licensing deals is $1.3B, based on 5 deals with disclosed terms from 2020--2025. Total deal values (including milestones) reach a median of $5.2B. Royalty rates typically range from 10.7% to 19.7%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| BioNTech | Bristol Myers Squibb | 2025 | $1.5B | $11.1B |
| Zymeworks | Jazz Pharmaceuticals | 2022 | $1.4B | $2.0B |
| 3SBio / Sunshine Guojian | Pfizer | 2025 | $1.3B | $6.3B |
Showing 3 of 5 deals with disclosed terms. Full comp set available in the report.
Full Bispecific Antibody phase-3 Comp Set
Get the complete analysis -- 5 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific bispecific antibody asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2020--2025). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.